The dispute centers on the production of semaglutide, the active ingredient in Novo’s blockbuster weight-loss medications. Hims & Hers recently announced it would offer the treatment for an introductory price of $49 for the first month as part of a five-month plan. This move directly challenges Novo Nordisk, which launched its own oral Wegovy pill in the United States last month at a starting price of $149 per month for a 1.5-milligram dose.

Regulatory and Safety Standoff

Novo Nordisk contends that the telehealth provider’s initiative bypasses critical federal safety standards. While compounding is permitted under certain conditions—such as during drug shortages—Novo argues that the scale of the Hims & Hers offering constitutes unauthorized manufacturing. The pharmaceutical company’s legal push follows its own official rollout, which received U.S. regulatory approval just weeks before hitting the market.

Hims & Hers has not yet responded to requests for comment regarding the litigation. The platform’s pricing strategy remains a significant disruption in the GLP-1 market, offering a tiered cost structure for its compounded version:

• Introductory first-month price: $49
• Subsequent monthly price (upfront): $99
• Novo Nordisk brand-name starting price: $149